S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
BREAKING: Tiny biotech successfully treats blindness (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
BREAKING: Tiny biotech successfully treats blindness (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
BREAKING: Tiny biotech successfully treats blindness (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
BREAKING: Tiny biotech successfully treats blindness (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
BREAKING: Tiny biotech successfully treats blindness (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
BREAKING: Tiny biotech successfully treats blindness (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
BREAKING: Tiny biotech successfully treats blindness (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
BREAKING: Tiny biotech successfully treats blindness (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
BREAKING: Tiny biotech successfully treats blindness (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
BREAKING: Tiny biotech successfully treats blindness (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
BREAKING: Tiny biotech successfully treats blindness (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
BREAKING: Tiny biotech successfully treats blindness (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
NASDAQ:GTHX

G1 Therapeutics (GTHX) Price Target & Analyst Ratings

$2.82
+0.20 (+7.63%)
(As of 06/5/2023 ET)
Compare
Today's Range
$2.73
$2.88
50-Day Range
$2.46
$3.14
52-Week Range
$2.38
$17.49
Volume
1.13 million shs
Average Volume
893,866 shs
Market Capitalization
$145.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.60

G1 Therapeutics Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 6 Analyst Ratings

Consensus Analyst Price Target

$16.60
488.65% Upside
High Prediction$25.00
Average Prediction$16.60
Low Prediction$10.00
TypeCurrent
6/6/22 to 6/6/23
1 Month Ago
5/7/22 to 5/7/23
3 Months Ago
3/8/22 to 3/8/23
1 Year Ago
6/6/21 to 6/6/22
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
5 Buy rating(s)
5 Buy rating(s)
5 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$16.60$16.60$16.60$38.67
Predicted Upside488.65% Upside158.33% Upside155.31% Upside230.44% Upside
Get G1 Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for GTHX and its competitors with MarketBeat's FREE daily newsletter.


GTHX Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

GTHX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

G1 Therapeutics Stock vs. The Competition

TypeG1 TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.83
2.66
2.48
Consensus RatingModerate BuyBuyHold
Predicted Upside488.65% Upside1,270.19% Upside219.79% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/19/2023Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$18.00+508.11%
3/2/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$11.00+199.73%
2/13/2023EF Hutton Acquisition Co. I
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$35.00 ➝ $19.00+468.86%
1/30/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderweight ➝ Neutral$7.00 ➝ $10.00+49.03%
1/4/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy
9/16/2022Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$20.00 ➝ $25.00+61.81%
(Data available from 6/6/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












GTHX Price Target - Frequently Asked Questions

What is G1 Therapeutics's consensus rating and price target?

According to the issued ratings of 6 analysts in the last year, the consensus rating for G1 Therapeutics stock is Moderate Buy based on the current 1 hold rating and 5 buy ratings for GTHX. The average twelve-month price prediction for G1 Therapeutics is $16.60 with a high price target of $25.00 and a low price target of $10.00. Learn more on GTHX's analyst rating history.

Do Wall Street analysts like G1 Therapeutics more than its competitors?

Analysts like G1 Therapeutics more than other Medical companies. The consensus rating for G1 Therapeutics is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how GTHX compares to other companies.

Does G1 Therapeutics's stock price have much upside?

According to analysts, G1 Therapeutics's stock has a predicted upside of 158.33% based on their 12-month price targets.

What analysts cover G1 Therapeutics?

G1 Therapeutics has been rated by Needham & Company LLC in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:GTHX) was last updated on 6/6/2023 by MarketBeat.com Staff

My Account -